Chemistry:Navamepent
From HandWiki
Navamepent (RX-10045) is a synthetic analogue[1] of the endogenous fatty acid resolvin E1, a member of the specialized pro-resolving mediators. Navamepent is presumed to act as an agonist of the CMKLR1 receptor in a manner similar to resolvin E1.
It was developed as a topical ophthalmic formulation to promote recovery from eye inflammation and advanced to Phase II clinical trials, but was not pursued further.[2][3][4]
References
- ↑ Gjorstrup P, Schwartz CE, "Compositions and methods for the treatment of inflammation", WO patent 2010120719, published 21 October 2010, assigned to Resolvyx Pharmaceuticals, Inc.
- ↑ "Resolvin E1 analog RX-10045 0.1% reduces corneal stromal haze in rabbits when applied topically after PRK". Molecular Vision 20: 1710–1716. 2014. PMID 25558174.
- ↑ "Resolvins and aliamides: lipid autacoids in ophthalmology - what promise do they hold?". Drug Design, Development and Therapy 10: 3133–3141. 2016. doi:10.2147/DDDT.S112389. PMID 27729772.
- ↑ "Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms". FASEB Journal 31 (4): 1273–1288. April 2017. doi:10.1096/fj.201601222R. PMID 28087575.
 |  |
